Peter Lerza
Nurse Practitioner · Seaford, DENPI 1316591647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $877 and has fallen 56.1% since, to $385 in 2025.
Across 107 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$404
- Lilly USA, LLC$315
- Novo Nordisk$277
- Biohaven Pharmaceuticals, Inc.$188
- Pfizer$145
- Amgen$114
- plus $784 from 19 others
What the payments were for
- Food & beverage$2,226100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $404 |
| Lilly USA, LLC | 13 | $315 |
| Novo Nordisk | 18 | $277 |
| Biohaven Pharmaceuticals, Inc. | 6 | $188 |
| Pfizer | 8 | $145 |
| Amgen | 5 | $114 |
| Exact Sciences | 5 | $106 |
| Gilead | 4 | $91 |
| Medtronic | 2 | $84 |
| Astellas Pharma US Inc | 4 | $80 |
| Bayer | 4 | $64 |
| Organogenesis Inc. | 2 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| AstraZeneca | 3 | $45 |
| Watermark Medical, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Dexcom, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $18 |
| Tris Pharma Inc | 1 | $18 |
| Resmed Corp | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Medicomp Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- MOUNJARO$100
How this compares
$2,226 in reported general payments places this provider in the 85th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $33,989 |
| MounjaroTirzepatide | 27 | $32,506 |
| EliquisApixaban | 30 | $24,566 |
| TrulicityDulaglutide | 13 | $20,580 |
| JardianceEmpagliflozin | 18 | $14,581 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,075 |
| BelsomraSuvorexant | 21 | $8,820 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,753 |
| Pregabalin | 11 | $1,052 |
| Triamcinolone Acetonide | 13 | $1,002 |
| Duloxetine Hcl | 54 | $975 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $903 |
| Azelastine Hcl | 36 | $775 |
| Gabapentin | 50 | $664 |
| Ondansetron OdtOndansetron | 38 | $563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $315 | $53,08640 claims |
| Novo NordiskOzempic | $277 | $33,98938 claims |
| PfizerEliquis | $145 | $24,56630 claims |
| Boehringer IngelheimJardiance | $18 | $14,58118 claims |
| MerckBelsomra | $30 | $8,82021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Seaford
- Meghan McCarterSeaford$170K
- Gayle WhaleySeaford$6K
- Sherry GardinerSeaford$6K
- Melissa KestlerSeaford$5K
- Cynthia KnightSeaford$4K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
- Jennifer HubbardWilmington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.